A dual agonist of farnesoid X receptor (FXR) and the G protein–coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice
Xiaoxin X. Wang(Beijing Obstetrics and Gynecology Hospital), Moshe Levi(University of Colorado Anschutz Medical Campus), Yuhuan Luo(University of Colorado Anschutz Medical Campus), Mark Pruzanski(University of Padua), Dong Wang(Sichuan University), Luciano Adorini(Intercept Pharmaceuticals (United States)), Evgenia Dobrinskikh(University of Colorado Anschutz Medical Campus)
Cited by 69
Related Papers
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
|Gastroenterology|2014|563
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Restructuring of the Gut Microbiome by Intermittent Fasting Prevents Retinopathy and Prolongs Survival in <i>db/db</i> Mice
|Diabetes|2018|385
SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy
|Journal of Biological Chemistry|2017|302